Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,033 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Bristol-Myers Squibb Clear all
Completed No phase listed Observational

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

NCT00998127
View directory record Official record
Conditions
Medication Non-adherence, Stent Thrombosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 11, 2026, 5:41 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT07221877
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/trospium chloride
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 11, 2026, 5:41 AM EDT
Active, not recruiting Phase 1 Interventional

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

NCT07333261
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BMS-986453
Drug
Lead sponsor
Susan Bal
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 11, 2026, 5:41 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

NCT07284745
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
29
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT02413372
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Rialto, California • San Diego, California • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

NCT00410072
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Entecavir + Tenofovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

NCT03605719
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Carfilzomib, Dexamethasone, Nivolumab, Pelareorep
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Metabolism Study in Healthy Male Participants

NCT03247283
View directory record Official record
Conditions
Cancer
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 11, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

NCT03411031
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 11, 2026, 5:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

NCT03635983
View directory record Official record
Conditions
Melanoma
Interventions
NKTR-214, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 11, 2026, 5:41 AM EDT
Recruiting No phase listed Observational

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

NCT05953402
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

NCT03831438
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
AVID200
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

NCT00570752
View directory record Official record
Conditions
Vascular Diseases
Interventions
Placebo, BMS-582949, Atorvastatin, Statin
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 4 Interventional

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

NCT02285985
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 11, 2026, 5:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

NCT06730750
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986490, Bevacizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 11, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes

NCT02863523
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes-related Distress, Depression
Interventions
Integrated Behavioral Care
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 75 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 11, 2026, 5:41 AM EDT